Targeted disruption of the BCL9/β-catenin complex inhibits oncogenic Wnt signaling

Science Translational Medicine

Volumn 4, Issue 148, 2012, Pages

  Takada, Kohichi ^a   Zhu, Di ^a   Bird, Gregory H ^b   Sukhdeo, Kumar ^a   Zhao, Jian Jun ^a   Mani, Mala ^a   Lemieux, Madeleine ^b   Carrasco, Daniel E ^a   Ryan, Jeremy ^a   Horst, David ^a   Fulciniti, Mariateresa ^a   Munshi, Nikhil C ^a   Xu, Wenqing ^c   Kung, Andrew L ^b   Shivdasani, Ramesh A ^a   Walensky, Loren D ^b   Carrasco, Daniel Ruben ^a,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; GLUTATHIONE TRANSFERASE; ONCOPROTEIN; PROTEIN BCL 9; UNCLASSIFIED DRUG; WNT PROTEIN;

ALPHA HELIX; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER INVASION; CELL MIGRATION; CELL PROLIFERATION; CIRCULAR DICHROISM; COLORECTAL CARCINOMA; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; IMMUNOPRECIPITATION; METASTASIS POTENTIAL; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; PROTEIN TARGETING; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

AMINO ACID SEQUENCE; ANIMALS; BETA CATENIN; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COLORECTAL NEOPLASMS; GENE TARGETING; HUMANS; INTESTINES; MICE; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; ONCOGENES; PEPTIDES; PROTEIN BINDING; PROTEIN STABILITY; PROTEIN STRUCTURE, SECONDARY; TCF TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; WNT SIGNALING PATHWAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84865315399     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3003808     Document Type: Article

References (57)

1. C. Y. Logan, R. Nusse, The Wnt signaling pathway in development and disease. Annu. Rev. Cell Dev. Biol. 20, 781-810 (2004).
2. H. Clevers, Wnt/β-catenin signaling in development and disease. Cell 127, 469-480 (2006).
3. A. Klaus, W. Birchmeier, Wnt signalling and its impact on development and cancer. Nat. Rev. Cancer 8, 387-398 (2008).
4. T. Valenta, G. Hausmann, K. Basler, The many faces and functions of β-catenin. EMBO J. 31, 2714-2736 (2012).
5. T. C. He, A. B. Sparks, C. Rago, H. Hermeking, L. Zawel, L. T. da Costa, P. J. Morin, B. Vogelstein, K. W. Kinzler, Identification of c-MYC as a target of the APC pathway. Science 281, 1509-1512 (1998).
6. O. Tetsu, F. McCormick, β-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398, 422-426 (1999).
7. T. Kramps, O. Peter, E. Brunner, D. Nellen, B. Froesch, S. Chatterjee,M.Murone, S. Züllig, K. Basler, Wnt/wingless signaling requires BCL9/legless-mediated recruitment of pygopus to the nuclear β-catenin-TCF complex. Cell 109, 47-60 (2002).
8. F. M. Townsley, A. Cliffe, M. Bienz, Pygopus and Legless target Armadillo/β-catenin to the nucleus to enable its transcriptional co-activator function. Nat. Cell Biol. 6, 626-633 (2004).
9. R. Hoffmans, R. Städeli, K. Basler, Pygopus and legless provide essential transcriptional coactivator functions to armadillo/β-catenin. Curr. Biol. 15, 1207-1211 (2005).
10. R. Städeli, K. Basler, Dissecting nuclear Wingless signalling: Recruitment of the transcriptional co-activator Pygopus by a chain of adaptor proteins. Mech. Dev. 122, 1171-1182 (2005).
11. C. Sustmann, H. Flach, H. Ebert, Q. Eastman, R. Grosschedl, Cell-type-specific function of BCL9 involves a transcriptional activation domain that synergizes with β-catenin. Mol. Cell. Biol. 28, 3526-3537 (2008).
12. F. H. Brembeck, T. Schwarz-Romond, J. Bakkers, S. Wilhelm, M. Hammerschmidt, W. Birchmeier, Essential role of BCL9-2 in the switch between β-catenin's adhesive and transcriptional functions. Genes Dev. 18, 2225-2230 (2004).
13. A. Hecht, K. Vleminckx, M. P. Stemmler, F. van Roy, R. Kemler, The p300/CBP acetyltransferases function as transcriptional coactivators of β-catenin in vertebrates. EMBO J. 19, 1839-1850 (2000).
14. J. Dutta-Simmons, Y. Zhang, G. Gorgun, M. Gatt, M. Mani, T. Hideshima, K. Takada, N. E. Carlson, D. E. Carrasco, Y. T. Tai, N. Raje, A. G. Letai, K. C. Anderson, D. R. Carrasco, Aurora kinase A is a target of Wnt/β-catenin involved in multiple myeloma disease progression. Blood 114, 2699-2708 (2009).
15. Y. W. Qiang, Y. Endo, J. S. Rubin, S. Rudikoff, Wnt signaling in B-cell neoplasia. Oncogene 22, 1536-1545 (2003).
16. K. Sukhdeo, M. Mani, Y. Zhang, J. Dutta, H. Yasui, M. D. Rooney, D. E. Carrasco, M. Zheng, H. He, Y. T. Tai, C. Mitsiades, K. C. Anderson, D. R. Carrasco, Targeting the β-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc. Natl. Acad. Sci. U.S.A. 104, 7516-7521 (2007).
17. P. W. Derksen, E. Tjin, H. P. Meijer, M. D. Klok, H. D. MacGillavry, M. H. van Oers, H. M. Lokhorst, A. C. Bloem, H. Clevers, R. Nusse, R. van der Neut, M. Spaargaren, S. T. Pals, Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc. Natl. Acad. Sci. U.S.A. 101, 6122-6127 (2004).
18. M. A. Chapman, M. S. Lawrence, J. J. Keats, K. Cibulskis, C. Sougnez, A. C. Schinzel, C. L.Harview, J. P. Brunet, G. J. Ahmann,M. Adli, K. C. Anderson, K. G. Ardlie, D. Auclair, A. Baker, P. L. Bergsagel, B. E. Bernstein, Y. Drier, R. Fonseca, S. B. Gabriel, C. C. Hofmeister, S. Jagannath, A. J. Jakubowiak, A. Krishnan, J. Levy, T. Liefeld, S. Lonial, S. Mahan, B. Mfuko, S. Monti, L. M. Perkins, R. Onofrio, T. J. Pugh, S. V. Rajkumar, A. H. Ramos, D. S. Siegel, A. Sivachenko, A. K. Stewart, S. Trudel, R. Vij, D. Voet, W. Winckler, T. Zimmerman, J. Carpten, J. Trent, W. C. Hahn, L. A. Garraway, M. Meyerson, E. S. Lander, G. Getz, T. R. Golub, Initial genome sequencing and analysis of multiple myeloma. Nature 471, 467-472 (2011).
19. M. Mani, D. E. Carrasco, Y. Zhang, K. Takada, M. E. Gatt, J. Dutta-Simmons, H. Ikeda, F. Diaz-Griffero, V. Pena-Cruz, M. Bertagnolli, L. L. Myeroff, S. D. Markowitz, K. C. Anderson, D. R. Carrasco, BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells. Cancer Res. 69, 7577-7586 (2009).
20. T. G. Willis, I. R. Zalcberg, L. J. Coignet, I. Wlodarska, M. Stul, D. M. Jadayel, C. Bastard, J. G. Treleaven, D. Catovsky, M. L. Silva, M. J. Dyer, Molecular cloning of translocation t(1;14)(q21;q32) defines a novel gene (BCL9) at chromosome 1q21. Blood 91, 1873-1881 (1998).
21. R. Beroukhim, C. H. Mermel, D. Porter, G. Wei, S. Raychaudhuri, J. Donovan, J. Barretina, J. S. Boehm, J. Dobson, M. Urashima, K. T. Mc Henry, R. M. Pinchback, A. H. Ligon, Y. J. Cho, L. Haery, H. Greulich, M. Reich, W. Winckler, M. S. Lawrence, B. A. Weir, K. E. Tanaka, D. Y. Chiang, A. J. Bass, A. Loo, C. Hoffman, J. Prensner, T. Liefeld, Q. Gao, D. Yecies, S. Signoretti, E. Maher, F. J. Kaye, H. Sasaki, J. E. Tepper, J. A. Fletcher, J. Tabernero, J. Baselga, M. S. Tsao, F. Demichelis, M. A. Rubin, P. A. Janne, M. J. Daly, C. Nucera, R. L. Levine, B. L. Ebert, S. Gabriel, A. K. Rustgi, C. R. Antonescu, M. Ladanyi, A. Letai, L. A. Garraway, M. Loda, D. G. Beer, L. D. True, A. Okamoto, S. L. Pomeroy, S. Singer, T. R. Golub, E. S. Lander, G. Getz, W. R. Sellers, M. Meyerson, The landscape of somatic copy-number alteration across human cancers. Nature 463, 899-905 (2010).
22. D. R. Carrasco, G. Tonon, Y. Huang, Y. Zhang, R. Sinha, B. Feng, J. P. Stewart, F. Zhan, D. Khatry, M. Protopopova, A. Protopopov, K. Sukhdeo, I. Hanamura, O. Stephens, B. Barlogie, K. C. Anderson, L. Chin, J. D. Shaughnessy Jr., C. Brennan, R. A. Depinho, High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 9, 313-325 (2006).
23. R. Rad, L. Rad, W. Wang, J. Cadinanos, G. Vassiliou, S. Rice, L. S. Campos, K. Yusa, R. Banerjee, M. A. Li, J. de la Rosa, A. Strong, D. Lu, P. Ellis, N. Conte, F. T. Yang, P. Liu, A. Bradley, PiggyBac transposon mutagenesis: A tool for cancer gene discovery in mice. Science 330, 1104-1107 (2010).
24. F. H. Brembeck, M. Wiese, N. Zatula, T. Grigoryan, Y. Dai, J. Fritzmann, W. Birchmeier, BCL9-2 promotes early stages of intestinal tumor progression. Gastroenterology 141, 1359-1370 (2011).
25. S. Adachi, T. Jigami, T. Yasui, T. Nakano, S. Ohwada, Y. Omori, S. Sugano, B. Ohkawara, H. Shibuya, T. Nakamura, T. Akiyama, Role of a BCL9-related β-catenin-binding protein, B9L, in tumorigenesis induced by aberrant activation of Wnt signaling. Cancer Res. 64, 8496-8501 (2004).
26. I. Sakamoto, S. Ohwada, H. Toya, N. Togo, K. Kashiwabara, T. Oyama, T. Nakajima, H. Ito, S. Adachi, T. Jigami, T. Akiyama, Up-regulation of a BCL9-related β-catenin-binding protein, B9L, in different stages of sporadic colorectal adenoma. Cancer Sci. 98, 83-87 (2007).
27. H. Toya, T. Oyama, S. Ohwada, N. Togo, I. Sakamoto, J. Horiguchi, Y. Koibuchi, S. Adachi, T. Jigami, T. Nakajima, T. Akiyama, Immunohistochemical expression of the β-catenin-interacting protein B9L is associated with histological high nuclear grade and immunohistochemical ErbB2/HER-2 expression in breast cancers. Cancer Sci. 98, 484-490 (2007).
28. J. Deka, N. Wiedemann, P. Anderle, F. Murphy-Seiler, J. Bultinck, S. Eyckerman, J. C. Stehle, S. André, N. Vilain, O. Zilian, S. Robine, M. Delorenzi, K. Basler, M. Aguet, Bcl9/Bcl9l are critical for Wnt-mediated regulation of stem cell traits in colon epithelium and adenocarcinomas. Cancer Res. 70, 6619-6628 (2010).
29. J. Sampietro, C. L. Dahlberg, U. S. Cho, T. R. Hinds, D. Kimelman, W. Xu, Crystal structure of a β-catenin/BCL9/Tcf4 complex. Mol. Cell 24, 293-300 (2006).
30. S. A. Kawamoto, A. D. Thompson, A. Coleska, Z. Nikolovska-Coleska, H. Yi, S.Wang, Analysis of the interaction of BCL9 with β-catenin and development of fluorescence polarization and surface plasmon resonance binding assays for this interaction. Biochemistry 48, 9534-9541 (2009).
31. S. A. Kawamoto, A. Coleska, X. Ran, H. Yi, C. Y. Yang, S. Wang, Design of triazole-stapled BCL9 a-helical peptides to target the β-catenin/B-cell CLL/lymphoma 9 (BCL9) protein-protein interaction. J. Med. Chem. 55, 1137-1146 (2012).
32. G. H. Bird, F. Bernal, K. Pitter, L. D. Walensky, Synthesis and biophysical characterization of stabilized α-helices of BCL-2 domains. Methods Enzymol. 446, 369-386 (2008).
33. L. D. Walensky, A. L. Kung, I. Escher, T. J. Malia, S. Barbuto, R. D. Wright, G. Wagner, G. L. Verdine, S. J. Korsmeyer, Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 305, 1466-1470 (2004).
34. G. H. Bird, N. Madani, A. F. Perry, A. M. Princiotto, J. G. Supko, X. He, E. Gavathiotis, J. G. Sodroski, L. D. Walensky, Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic. Proc. Natl. Acad. Sci. U.S.A. 107, 14093-14098 (2010).
35. L. G. Van der Flier, J. Sabates-Bellver, I. Oving, A. Haegebarth, M. De Palo, M. Anti, M. E. Van Gijn, S. Suijkerbuijk, M. Van de Wetering, G. Marra, H. Clevers, The intestinal Wnt/TCF signature. Gastroenterology 132, 628-632 (2007).
36. F. Bernal, A. F. Tyler, S. J. Korsmeyer, L. D. Walensky, G. L. Verdine, Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide. J. Am. Chem. Soc. 129, 2456-2457 (2007).
37. H. Brooks, B. Lebleu, E. Vivès, Tat peptide-mediated cellular delivery: Back to basics. Adv. Drug Deliv. Rev. 57, 559-577 (2005).
38. B. Lustig, B. Jerchow, M. Sachs, S. Weiler, T. Pietsch, U. Karsten, M. van de Wetering, H. Clevers, P. M. Schlag, W. Birchmeier, J. Behrens, Negative feedback loop of Wnt signaling through upregulation of conductin/axin2 in colorectal and liver tumors. Mol. Cell. Biol. 22, 1184-1193 (2002).
39. X. Zhang, J. P. Gaspard, D. C. Chung, Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. Cancer Res. 61, 6050-6054 (2001).
40. B. Zirn, B. Samans, S. Wittmann, T. Pietsch, I. Leuschner, N. Graf, M. Gessler, Target genes of the WNT/β-catenin pathway in Wilms tumors. Genes Chromosomes Cancer 45, 565-574 (2006).
41. T. A. Chan, Z. Wang, L. H. Dang, B. Vogelstein, K. W. Kinzler, Targeted inactivation of CTNNB1 reveals unexpected effects of β-catenin mutation. Proc. Natl. Acad. Sci. U.S.A. 99, 8265-8270 (2002).
42. P. Tassone, P. Neri, D. R. Carrasco, R. Burger, V. S. Goldmacher, R. Fram, V. Munshi, M. A. Shammas, L. Catley, G. S. Jacob, S. Venuta, K. C. Anderson, N. C. Munshi, A clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood 106, 713-716 (2005).
43. N. Barker, H. Clevers, Mining the Wnt pathway for cancer therapeutics. Nat. Rev. Drug Discov. 5, 997-1014 (2006).
44. M. Lepourcelet, Y. N. Chen, D. S. France, H. Wang, P. Crews, F. Petersen, C. Bruseo, A. W. Wood, R. A. Shivdasani, Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex. Cancer Cell 5, 91-102 (2004).
45. T. Reya, H. Clevers, Wnt signalling in stem cells and cancer. Nature 434, 843-850 (2005).
46. K. H. Emami, C. Nguyen, H. Ma, D. H. Kim, K. W. Jeong, M. Eguchi, R. T. Moon, J. L. Teo, H. Y. Kim, S. H. Moon, J. R. Ha, M. Kahn, A small molecule inhibitor of β-catenin/CREB-binding protein transcription. Proc. Natl. Acad. Sci. U.S.A. 101, 12682-12687 (2004).
47. B. Chen, M. E. Dodge, W. Tang, J. Lu, Z. Ma, C. W. Fan, S. Wei, W. Hao, J. Kilgore, N. S. Williams, M. G. Roth, J. F. Amatruda, C. Chen, L. Lum, Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat. Chem. Biol. 5, 100-107 (2009).
48. S. M. Huang, Y. M. Mishina, S. Liu, A. Cheung, F. Stegmeier, G. A. Michaud, O. Charlat, E. Wiellette, Y. Zhang, S. Wiessner, M. Hild, X. Shi, C. J. Wilson, C. Mickanin, V. Myer, A. Fazal, R. Tomlinson, F. Serluca, W. Shao, H. Cheng, M. Shultz, C. Rau, M. Schirle, J. Schlegl, S. Ghidelli, S. Fawell, C. Lu, D. Curtis, M. W. Kirschner, C. Lengauer, P. M. Finan, J. A. Tallarico, T. Bouwmeester, J. A. Porter, A. Bauer, F. Cong, Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 461, 614-620 (2009).
49. C. A. Thorne, A. J. Hanson, J. Schneider, E. Tahinci, D. Orton, C. S. Cselenyi, K. K. Jernigan, K. C. Meyers, B. I. Hang, A. G. Waterson, K. Kim, B. Melancon, V. P. Ghidu, G. A. Sulikowski, B. LaFleur, A. Salic, L. A. Lee, D. M. Miller III, E. Lee, Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α. Nat. Chem. Biol. 6, 829-836 (2010).
50. P. Polakis, Drugging Wnt signalling in cancer. EMBO J. 31, 2737-2746 (2012).
51. L. K. Henchey, A. L. Jochim, P. S. Arora, Contemporary strategies for the stabilization of peptides in the a-helical conformation. Curr. Opin. Chem. Biol. 12, 692-697 (2008).
52. G. H. Bird, W. C. Crannell, L. D. Walensky, Chemical synthesis of hydrocarbon-stapled peptides for protein interaction research and therapeutic targeting. Curr. Protoc. Chem. Biol. 3, 99-117 (2011).
53. M. de la Roche, T. J. Rutherford, D. Gupta, D. B. Veprintsev, B. Saxty, S. M. Freund, M. Bienza, An intrinsically labile a-helix abutting the BCL9-binding site of β-catenin is required for its inhibition by carnosic acid. Nat. Commun. 3, 680 (2012).
54. Y. Shang, X. Hu, J. DiRenzo, M. A. Lazar, M. Brown, Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103, 843-852 (2000).
55. R. L. Clifford, K. Deacon, A. J. Knox, Novel regulation of vascular endothelial growth factor-A (VEGF-A) by transforming growth factor β1: Requirement for Smads, β-catenin, and GSK3β. J. Biol. Chem. 283, 35337-35353 (2008).
56. A. Basu, A. G. Contreras, D. Datta, E. Flynn, L. Zeng, H. T. Cohen, D. M. Briscoe, S. Pal, Overexpression of vascular endothelial growth factor and the development of post-transplantation cancer. Cancer Res. 68, 5689-5698 (2008).
57. L. Naldini, U. Blomer, F. H. Gage, D. Trono, I. M. Verma, Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc. Natl. Acad. Sci. U.S.A. 93, 11382-11388 (1996).